With the aim of achieving localized pharmaceutical manufacturing and supply in Africa as well as enhancing the accessibility and affordability of pharmaceutical and healthcare products in the African region, Fosun Pharma is implementing a "three-step" strategic plan involving building infrastructure, improving production lines, and expanding project capacity to advance the construction of the Cote d’Ivoire park project. The first phase of the Cote d’Ivoire park project is expected to be completed in 2024. Upon full completion of the project, the production capacity will reach 5 billion tablets per year and include a warehouse with a storage capacity of 10,000 pallets, which is expected to bring nearly 1,000 job opportunities to the Grand Bassam area and effectively promote the development of the pharmaceutical industry in Cote d'Ivoire.

Fosun Pharma’s Cote d’Ivoire park project was initiated in November 2022. Guilin Pharma, a member company of Fosun Pharma, actively responded to the “Belt and Road” initiative by launching the Cote d’Ivoire pharmaceutical production facility project in the Grand Bassam area in Abidjan;

In 2023, International Finance Corporation (IFC) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. established a partnership. Under the partnership, IFC will provide subsidiaries of Fosun Pharma with two loans totaling EUR50 million to support the construction of a manufacturing site near Abidjan to produce antimalarial drugs and antibacterial medicines, which is Fosun Pharma’s Cote d’Ivoire park project;

The project is planned to be carried out in three phases, with the first phase expected to be completed in 2024.

Cote d'Ivoire, located on the Gulf of Guinea in West Africa, has gained a renowned reputation across the African continent for its outstanding economic development achievements. Abidjan, the economic capital of Cote d’Ivoire, is known as the "Paris of West Africa" due to its unique charm.

In November 2022, Guilin Pharma, a member company of Fosun Pharma, actively responded to the “Belt and Road” initiative by launching the Cote d’Ivoire pharmaceutical production facility project in the Grand Bassam area in Abidjan. Guilin Pharma plans to introduce its proprietary artemisinin-based antimalarial drugs into Africa and establish local production, while ensuring significant efficacy and high quality control, building Guilin Pharma into a flagship "Artemisia industry" brand under Fosun Pharma.

To support stronger healthcare delivery and outcomes in West Africa, IFC and Fosun Pharma have established a partnership to help Fosun Pharma build a pharmaceutical production facility and distribution hub in Cote d’Ivoire. Under the partnership, IFC will provide subsidiaries of Fosun Pharma with two loans totaling EUR50 million to support the construction of a manufacturing site near Abidjan to produce antimalarial drugs and antibacterial medicines, which is Fosun Pharma’s Cote d’Ivoire park project.

Looking ahead, Fosun Pharma's Cote d’Ivoire park project will follow a "three-step" strategic plan involving building infrastructure, improving production lines, and expanding project capacity. Upon completion of the project, the drug production capacity is expected to reach 5 billion tablets per year and include a warehouse with a storage capacity of 10,000 pallets.

The company will have a complete production line that meets the Current Good Manufacturing Practice (cGMP) standards locally. The project is set to become the largest, most comprehensive, and most stringently managed demonstration facility in West Africa, which will help the region gain access to more high-quality and affordable life-saving drugs. The project aspires to serve as a model for China-Africa medical and health cooperation and contributing to the China-Africa health community.

Malaria is a global public health concern that poses a serious threat to people's health and lives, impacting social and economic development. The United Nations has listed "Ending Malaria" as a Millennium Development Goal.

In 2015, Chinese scientist Tu Youyou won the Nobel Prize in Physiology or Medicine 2015 for her discovery of the extraction method of artemisinin and her remarkable contribution to the global malaria treatment. She became the first Chinese recipient of this award. However, Tu Youyou was not alone in the fight against malaria. Guilin Pharma, a member company of Fosun Pharma, not only participated in the "523 Project" that led to the advent of artemisinin like Tu Youyou, but also developed artesunate, a wonder drug for the treatment of malaria, making large-scale prevention and treatment of malaria a reality. According to the World Health Organization's "World Malaria Report 2023", there were 249 million new malaria cases and 608,000 malaria deaths in the world in 2022. The sub-Saharan Africa  region accounted for more than 95% of malaria cases and deaths worldwide. Between 2000 to 2022, it was estimated that 11.7 million deaths caused by malaria were adverted globally. In Africa, the average malaria mortality rate (deaths per 100,000 population at risk) per 100,000 population dropped from 142.6 per 100,000 population at risk in 2000 to 55.5 per 100,000 population at risk in 2022, down from 0.14% to 0.055%. One of the key factors behind this success was due to the widespread use of artemisinin-based drugs. Multiple global multi-center phase III clinical trials and real-world data have shown that artesunate for injection can effectively help reduce malaria mortality rate. The local production of artemisinin-based antimalarial drugs will effectively lower drug costs and benefit more malaria patients, making a positive contribution to the elimination of malaria in West African countries.

The Cote d’Ivoire project is a "bridgehead" for Guilin Pharma’s strategy to develop the African pharmaceutical market. Since the project was launched, the leaders of Guilin Pharma have been closely monitoring the progress. In 2023, Guilin Pharma’s Chairman Xu Xiaoping and President Peng Xiaodan led the quality and production managers to make multiple visits to the Cote d’Ivoire park project site. They have conducted on-site inspections and evaluations of the project’s construction progress. The leaders have also led the team to visit local hospitals, pharmacies and other target customers, and held research and discussion meetings to address the pain points and challenges to ensure the smooth and steady advancement of the project. During the construction process, Guilin Pharma not only realized the local drug production, but also gradually localized the management of technical personnel by conducting technical training for local African employees and offering continuing education programs provided by China. In addition, the company has strengthened cooperation with drug regulatory authorities in West African countries and established a Good Manufacturing Practice (GMP) training base, helping to cultivate a pool of outstanding pharmaceutical technical talents in West Africa. This "Made in Africa and Use in Africa" project is expected to bring nearly 1,000 job opportunities to the Grand Bassam area, effectively driving the development of the pharmaceutical industry in Cote d'Ivoire and helping enhance Cote d'Ivoire's influence in the field of medicine and health in West Africa.